A new era of the clinical trial: How immuno-oncology advances are reshaping traditional clinical development paradigms

Reviewing recent advancements in oncology clinical trial design and execution, and exploring challenges and opportunities for effective patient therapies.

Combining multiple therapies for metastatic breast cancer ADCs and ICIs

Review of how ADCs and ICIs combined use can significantly improve outcomes in patients with metastatic breast cancer.

Chimeric antigen receptor T-cell publication spotlight: our top recent peer-reviewed journal articles featuring Fortrea oncologists discussing CAR-T drug development

CAR-T cell therapies represent a breakthrough. Read Fortrea's oncology team contributions to CAR-T peer-reviewed journal articles in this information sheet.

Antibody-drug conjugate publication spotlight: our top recent peer-reviewed journal articles featuring Fortrea oncologists discussing ADC drug development

Antibody-drug conjugates are an exciting advance in cancer therapeutics. Read about Fortrea's oncology team contributions to ADC peer-reviewed journal articles.

The importance of early integration of liquid biopsy to enhance oncology research

Pricing and reimbursement in Germany: At a glance

Frank Cohen, MD, BSc

Frank is a medical director at Fortrea. He has earned his degree in Medicine at the University of Amsterdam and has a bachelor’s degree in biomolecular science.

Jonathan Gerst, MBA

Jonathan has over 20 years of clinical trial experience in early clinical and late-stage studies holding roles within Clinical Operations and Project Management.

Julie Churchill

Julie is a Delivery Director partnering closely with sponsors and stakeholders across our core Renal Therapeutic team.